Investors

Corporate Profile

Xtant Medical Holdings, Inc. (NYSE MKT: XTNT) develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. Xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and...
More

Stock Quote
XTNT (Common Stock)
Price$0.58
Change (%)0.00 (0.00%)
Volume0
Data as of 01/13/17 3:58 p.m. ET
Refresh quote

Data provided by Nasdaq. Minimum 15 minutes delayed.

Stock Chart
Stock chart for: XTNT.K.  Currently trading at $0.58 with a 52 week high of $3.75 and a 52 week low of $0.45.
Recent News
DateTitle 
01/13/17XTNT Announces Registered Direct Offering
BELGRADE, Mont., Jan. 13, 2017 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, today has announced that it has entered into an agreement with certain holders of its convertible promissory notes (“Indenture Notes”) to purchase shares of Xtant's common stock in a registered direct offering conducted without an underwriter or placement agent (the "Offering"). ... 
01/11/17XTNT Announces Preliminary Fourth Quarter and Full Year 2016 Revenue & Adjusted EBITDA
Record Fourth Quarter 2016 Revenue is estimated to be at least $24.5 million which represents 10.0% year on year growth Full Year 2016 Revenue is estimated to be at least $90.0 million which represents 4.1% year on year growth Fourth Quarter 2016 Adjusted EBITDA* is estimated to be at least $1.25 million versus a loss of $350,000 in the Fourth Quarter of 2015 Full Year 2016 Adjusted EBITDA* is estimated to be at least $2.2 million versus a pro forma loss of $33,000 for the Full Ye... 
11/23/16Xtant Medical Receives FDA Clearance for the Xsert™ Lumbar Expandable Interbody System
BELGRADE, Mont., Nov. 23, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development of regenerative medicine products and medical devices, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Xsert Lumbar Expandable Interbody System. The Xsert System is an all titanium expandable interbody device that expands in-situ. It is available in various sizes and lordotic angulations to fit the most complex anatomical needs of pati... 
11/17/16Xtant Medical Closes Rights Offering for Gross Proceeds of $3.8 Million
BELGRADE, Mont., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE MKT:XTNT), a leader in the development, manufacturing and marketing of orthopedic products for domestic and international markets, announced today the closing of its rights offering (the "Offering") of units at a subscription price of $0.75 per unit, for aggregate gross proceeds to the Company of approximately $3.8 million. Pursuant to the Rights Offering, Xtant sold an aggregate of 5,055,345 units consistin... 
More

Upcoming Events
There are currently no events scheduled.
More

Receive E-mail Alerts
Sign up to receive e-mail alerts whenever Xtant Medical Holdings Inc posts new information to the site. Just enter your e-mail address and click Submit.